A Randomized Trial to Evaluate Effectiveness of Acetazolamide in COPD Patients Developing Metabolic Alkalosis During Invasive Mechanical Ventilation
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 380
- 试验地点
- 1
- 主要终点
- length of invasive mechanical ventilation
研究概览
简要总结
The purpose of this study is to determine whether acetazolamide are effective to reduce the length of mechanical ventilation in decompensated Chronic Obstructive Pulmonary Disease (COPD) patients developing pure or mixed metabolic alkalosis.
详细描述
The purpose of this study is to determine whether acetazolamide is effective to reduce the length of mechanical ventilation in decompensated COPD patients developing pure or mixed metabolic alkalosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Decompensated COPD on invasive mechanical ventilation Less than 24 hours
排除标准
- 未提供
研究组 & 干预措施
Acetazolamide
Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
干预措施: Acetazolamide (Drug)
Placebo
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
length of invasive mechanical ventilation
时间窗: within the first 28 days after intubation
次要结局
- numbers of nosocomial infections(every day during 28 days)
- length of ICU stay(once at the end of ICU stay or at Day 28)
- ICU mortality(once at the end of ICU stay or at Day 28)
- Length of weaning from mechanical ventilation(once at the extubation or at day 28)
- weaning success(once at the end of ICU stay or at Day 28)